sporty investor
14 Mar 2018
Re: Results etc Chienese authorities Approval for the first drug candidate is vital. Until then, unless some other ‘positive news’ is provided, slow drift of share price can be expected. Perhaps, good for those patient investors to accumulate cheaply.DG, is any ‘monetary value’ provided by the CEO for Chinese approval for the first drug? Thanks,
Kingel
13 Mar 2018
The Guardian Why hasn’t Aim hailed Chi-Med success?[link] companies on London’s junior stock market, the Alternative Investment Market, claim about 90% of the attention. That’s understandable, since fashion retailer Asos, the biggest, and tonic water upstart Fever-Tree, the third biggest, are well-known firms that have been superb investments.What’s the second biggest? It’s Hutchison China MediTech, or Chi-Med, which has performed just as well. The firm first was mentioned in this column as long ago as 2009 when share price was 200p. Now the shares are £51.40, giving a stock market value of £3.45bn. Chi-Med is the first serious attempt to build a Chinese-based international pharmaceutical firm, and the project is plainly going well. Monday’s full-year numbers continued the smooth progress. Fruquintinib, a colorectal cancer treatment being developed with US pharma giant Lilly, could be launched in China later this year. Savolitinib, for lung cancer, is partnered with AstraZeneca and being tested in combination with some of the UK’s firm’s established drugs.Nothing is guaranteed in the drug-development game, but Chi-Med’s soaring valuation points to investor interest, especially in the US, where the firm now has joint listing on Nasdaq. The Aim market has its critics, but the criticism in this case is that London has not done enough to shout about a big success. If there were more Chi-Meds, nobody would care about titans such as Saudi Aramco.[link]
David Global
12 Mar 2018
FY17 Results Three critical points for me:-1. Chi-Med is comfortable with, and actually sees advantages in Lilly not taking up global rights to Fruquintinib as they are gearing up on the U.S Regulatory side, so can now go it alone outside China2. AZ have said they will proceed into final stages of development with Tagrisso globally3. The fact the Company is setting up their own Regulatory Team based in the United States is important - they can push approval for Fruq (if Lilly do not take ex China rights) and for unpartnered drugs in the future - that is massive
sporty investor
10 Mar 2018
Re: Results etc DG, it was AIM.(How ever, last evening, I tried unsuccessfully, to buy some nasdaq quoted shares at $36.5.) I remain very positive.
David Global
10 Mar 2018
Re: Results etc sporty - On AIM or NASDAQ?Maybe it was just some re-balancing between ADR's and ordinary shares as if you buy either sometimes the Marketmakers will do a trade between the two.....
sporty investor
09 Mar 2018
Re: Results etc DG, thanks for the update and your opinion.Just curious about the big trades that have taken place, after market closure, yesterday and today. Looking at the trade prices it’s difficult to say whether these were buys or sells.
David Global
09 Mar 2018
Re: Results etc Annual Results, 7am on MondayI am looking forward to the numbers and of course the 2018 forward guidance but the most interesting part will be updates on Fruquintinib (especially what Lilly are doing with regards to global rights) and Savolitinib (especially what AZ are planning to do with regards to seeking BT designation)
David Global
21 Feb 2018
Results etc Annual Results will be announced on Mon 12th March but also expect significant updates on or large pipeline.Speaking of the pipeline I wonder why we've not had an update on Savolitinib and AZ's strategy for getting it approved via BT or getting it through Phase 3.Ad what about Eli Lilly's decision to take up global rights to Fruquintinib? They had an opp one year ago and they have another opp right now.
David Global
06 Feb 2018
Re: A big fall sometimes there is a disparity between the prices when using the wholesale exchange rate but I notice it usually corrects itself. The Co website has some info about this aspect and it's interesting to note that UK MM's can buy ADR's to satisfy a UK order and U.S MM's can also buy AIM shares to satisfy a U.S order. In other words they all have access to both pools of stock to satisfy any buy/sell orders.
David Global
06 Feb 2018
Re: Lacking news sporty - I agree. My understanding from the Management Team is that Eli Lilly had one more chance to take up global rights (ex China) to Fruquintinib by about March 2018. This topic will almost certainly come up at the Analyst meeting on the 13th March, which will be webcast.As for Savolitinib my understanding is additional data was being presented to and discussed with the FDA in order to make a decision on whether to go down the Breakthrough therapy route.I agree an update on both topics is required and probably expected! I am sure we will hear shortly, either prior to the Annual Results day, or shortly before. Either one of these would be quite material and provide a welcome re-boost to the share price.
sporty investor
05 Feb 2018
Lacking news Lacking updates about Eli Lilly’s decision about Fruquintinib and AZ’s about Savolitinib. The former has been pending for sometime, if I am correct. Any update from the company will be very helpful to all concerned.
Sharpedge7
05 Feb 2018
Nasdaq So this finished up on NDQ on Friday, only a bit admittedly...but now down 7% here....not brave enough to buy more but would if I was not already investing a lot here (probably too much).
Sharpedge7
25 Jan 2018
Re: A big fall well I bought more yesterday - not sure I understand the correlation between the prices of the two listings and sterling v dollar rate but obviously Nasdaq price is off its highs too and I bought on that weakness, hopefully temporary!
David Global
25 Jan 2018
Re: A big fall I am biased bu time to get IN not OUT when you think we have a lot of material news coming any day including:-1. CFDA Fruquintinib approval 2. Lilly decision on global rights to Fruquintinib 3. AZ decision on Savolitinib and poss Breakthrough Therapy designation 4. FY17 results Plus many other things!Part of the price drop in the UK is because sterling has gone from $1.33 to $1.40 in the last 2 weeks and NASDAQ drives the price now.We are due more material news in the next few weeks and months than we've had in the last 10 years so anyone selling now may regret it in 6 months time, but I accept everyone has different entry and exit points and profit targets.Personally I am a long term Investor so I continue to buy.
Sharpedge7
24 Jan 2018
Re: A big fall Nasdaq ADSs fell 5% yesterday but up 4.36% today as I write - so should bounce if that stands. Might have been a rare buying opportunity? Who knows...[link]
